Overview
News
Salaries
Products
People
Growth
Offices
Financials

Overview

VedaBio is developing a first-in-class syndromic panel for the point of care. An amplification-free CRISPR platform designed to bring molecular accuracy to urgent care with antigen simplicity.

News

News YahooFinance 15 days ago
VedaBio Appoints Valerie R. Dixon to Board of Directors
SAN DIEGO, September 16, 2026--VedaBio Appoints Valerie R. Dixon to Board of Directors
Read more
Report
News Pulse 2.0 3 years ago
VedaBio: Molecular Detection Company Raises Over $40 Million In Funding
VedaBio - a biotechnology company focused on molecular detection - recently launched with over $40 million in funding backed by lead investor OMX Ventures and a select group of family offices, including Kleinmuntz Associates. VedaBio also unlocked the tru
Read more
Report
News Pulse 2.0 3 years ago
VedaBio: Over $40 Million Raised To Transform Molecular Detection
VedaBio - the biotechnology company driving a paradigm shift in molecular detection - launched today with initial funding of over $40 million backed by lead investor OMX Ventures along with a select group of family offices, including Kleinmuntz Associates
Read more
Report